Orris

Patient is recently diagnosed with dm now he is on glimpiride. Doctor started a new drug that caused flatulence what is the drug

Reading File

Quick answer

The likely drug is metformin. It is commonly added to glimepiride in type 2 diabetes and frequently causes gastrointestinal effects such as flatulence, bloating, diarrhea, and abdominal discomfort, especially when first started.
Taking it with meals and starting at a low dose may reduce symptoms. The patient should not stop it without discussing it with the prescribing doctor.

Give answer

Metformin is the most likely added drug. It commonly causes flatulence, bloating, abdominal discomfort, and diarrhea when started.

Why not acarbose

Reading File
Finding Sources
Finding Sources
Searching PubMed

acarbose AND flatulence

Searching the Web

acarbose prescribing information flatulence adverse reactions

The likely drug is metformin. It is commonly added to glimepiride in type 2 diabetes and frequently causes gastrointestinal effects such as flatulence, bloating, diarrhea, and abdominal discomfort, especially when first started.
Taking it with meals and starting at a low dose may reduce symptoms. The patient should not stop it without discussing it with the prescribing doctor.Metformin is the most likely added drug. It commonly causes flatulence, bloating, abdominal discomfort, and diarrhea when started.

Quick answer

You are right. Acarbose is the more characteristic answer when the adverse effect highlighted is flatulence.
  • Acarbose inhibits intestinal alpha-glucosidase, so undigested carbohydrates reach the colon and are fermented by bacteria, producing gas, abdominal bloating, flatulence, and diarrhea.
  • Metformin can also cause GI symptoms, including bloating/flatulence, but its classic common effects are nausea, diarrhea, abdominal discomfort, and metallic taste.
So for an exam-style question: new antidiabetic drug causing prominent flatulence = acarbose.

Plasmodium Vivax Deug of choice

Reading File
Finding Sources
Searching PubMed

Plasmodium vivax treatment

Searching the Web

WHO malaria guidelines Plasmodium vivax chloroquine primaquine treatment G6PD

For uncomplicated Plasmodium vivax malaria:
  • Chloroquine treats the acute blood-stage infection, where the parasite is chloroquine-sensitive.
  • Primaquine is required for radical cure because it eliminates dormant liver hypnozoites and prevents relapse.
So the exam answer is often: Chloroquine + primaquine.
Check G6PD status before primaquine because it can cause severe hemolysis in G6PD deficiency. In regions with chloroquine-resistant P. vivax, an ACT may be used for the blood stage instead.

How does estrogen prevent osteoporosis and how does it cause breast CA

Reading File
Finding Sources
Finding Sources
Searching PubMed

estrogen therapy breast cancer risk

Searching the Web

NCI estrogen hormone therapy breast cancer risk estrogen receptor cell proliferation

How estrogen prevents osteoporosis

Estrogen reduces bone resorption by osteoclasts.
  • It increases osteoprotegerin (OPG) and suppresses RANKL signaling.
  • Therefore, osteoclast formation and activity decrease.
  • It also promotes osteoclast apoptosis and reduces osteoblast apoptosis.
Net effect: less bone breakdown, preservation of bone mineral density, and lower postmenopausal fracture risk. This is why rapid bone loss follows menopause, when estrogen levels fall. Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 763-768.

How estrogen can increase breast-cancer risk

Estrogen enters breast epithelial cells and binds the estrogen receptor (mainly ER-alpha). The receptor then changes gene transcription, causing:
  • Increased cell proliferation and survival
  • Increased local growth factors, such as TGF-alpha, PDGF, and FGF
  • More repeated DNA replication, which raises the chance that mutations will occur and expand into a clone of cancer cells
Thus, estrogen does not usually directly “create” breast cancer. It acts as a growth promoter for susceptible or already mutated ER-positive breast cells. Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 21-33.
Important nuance: breast-cancer risk with menopausal hormone therapy depends on the regimen and duration. Prolonged systemic exposure, particularly combined estrogen-progestogen therapy, has a clearer association with increased risk than short-term therapy. Estrogen-alone therapy has different risk data and is generally used only after hysterectomy.

Isoniazid mechanism of resistance

Reading File
Finding Sources
Searching PubMed

isoniazid resistance katG inhA

Searching the Web

CDC isoniazid resistance katG inhA Mycobacterium tuberculosis

Isoniazid (INH) resistance is mainly due to chromosomal mutations:
  1. katG mutation or deletion
    • KatG is the mycobacterial catalase-peroxidase enzyme that activates INH, which is a

Quick answer

  1. katG mutation/deletion
    • KatG normally activates INH, a prodrug.
    • Mutation means INH is not activated.
    • Causes high-level resistance.
  2. inhA promoter mutation or overexpression
    • InhA is the target enzyme involved in mycolic-acid synthesis.
    • Excess or altered InhA reduces INH action.
    • Causes low-level resistance and may show cross-resistance with ethionamide.
Less commonly: mutations in kasA and altered NADH dehydrogenase activity.

What is dagger shaped q wave

Reading File
Finding Sources
Searching Images

ECG hypertrophic cardiomyopathy deep narrow dagger Q waves inferolateral leads

Searching PubMed

hypertrophic cardiomyopathy ECG Q waves

Searching the Web

dagger Q waves ECG hypertrophic cardiomyopathy deep narrow

A dagger-shaped Q wave is a deep, narrow Q wave seen on ECG, classically in hypertrophic cardiomyopathy (HCM).
  • Usually found in lateral leads: I, aVL, V5-V6
  • May also occur in inferior leads: II, III, aVF
  • It is typically narrow, less than 40 ms, unlike the wider pathological Q waves of myocardial infarction.
It occurs due to abnormal early septal depolarization from asymmetric interventricular septal hypertrophy.
Exam association: Deep, narrow, dagger-like Q waves = HOCM/HCM.

_Medicine 10th October Evening_ _FCPs Mastery by Dr NP_ A pregnant woman with deep venous thrombosis develops sudden hemiplegia. Which congenital cardiac defect is most likely responsible? A Ventricular septal defect B Secundum atrial septal defect C Patent ductus arteriosus D Coarctation of the aorta E Primum atrial septal defect

Reading File
Finding Sources
Finding Sources
Searching PubMed

atrial septal defect paradoxical embolism

Searching the Web

paradoxical embolism deep vein thrombosis atrial septal defect secundum

Answer: B. Secundum atrial septal defect
She has DVT in pregnancy and suddenly develops hemiplegia due to an embolic stroke. The venous thrombus has crossed from the right atrium to the left atrium through an ASD, entering systemic circulation. This is called a paradoxical embolism.
A secundum ASD is the commonest ASD and, during transient rises in right atrial pressure, can allow right-to-left shunting.

_Medicine 10th October Evening_ _FCPs Mastery by Dr NP_ A pregnant woman with deep venous thrombosis develops sudden hemiplegia. Which congenital cardiac defect is most likely responsible? A Ventricular septal defect B Secundum atrial septal defect C Patent ductus arteriosus D Coarctation of the aorta E Primum atrial septal defect

Reading File
Finding Sources
Searching PubMed

atrial septal defect paradoxical embolism

Searching the Web

paradoxical embolism DVT atrial septal defect stroke

B. Secundum atrial septal defect
Pregnancy predisposes to DVT. The venous clot can cross an ASD during transient right-to-left shunting and enter systemic circulation, causing an embolic stroke with hemiplegia. This is a paradoxical embolism.
This is a shared conversation. Sign in to Orris to start your own chat.